• Explore /
  • Poster
  • / A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations.

A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations.

Abstract Poster

Authors

null

Daneng Li

Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA

Daneng Li , Eric Xueyu Chen , Zishuo Ian Hu , David Hsieh , Jimmy J. Hwang , Lynn G. Feun , Joseph Wang Franses , Gentry Teng King , Thomas Drake , Toshiyasu Suzuki , Thomas G Bird , Stephen Horrigan , Jean Chang , David D. Stenehjem , Casey Cunningham

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT05797805

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS4192)

DOI

10.1200/JCO.2024.42.16_suppl.TPS4192

Abstract #

TPS4192

Poster Bd #

166a

Abstract Disclosures

Similar Posters

First Author: Minal A. Barve

First Author: Nataliya Mar

First Author: Martin David Forster

First Author: Benjamin Philip Levy